As such, in this study investigating patients with newly diagnosed, histologically proven and treatment-naïve PC at time of scan, we observed a high prevalence of lesions with intense uptake (PSMA-RADS-4 and -5, 39.5%) as well as of lesions with equivocal uptake (PSMA-RADS-3A or -3B, 20.9%) [27]. The gene discussed is FOLH1; the disease is pachyonychia congenita.